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Acute kidney injury (AKI) is associated with adverse 
outcomes, including worse short- and long-term mortality, 
increased length of hospital stay and development of 
chronic kidney disease (CKD) (1). Iodinated contrast has 
been associated with AKI since its use began in the middle 
of the 20th century, termed contrast induced nephropathy 
and later contrast induced acute kidney injury (CI-AKI). 
Studies on the underlying pathogenesis have mainly been 
limited to animal models (2). With the development of 
newer contrast types, low osmolar contrast media and iso-
osmolar contrast media that have replaced high osmolar 
contrast media, the importance of contrast in development 
of AKI has been questioned (3). The term contrast 
associated AKI (CA-AKI) or post-contrast exposure AKI 
have now been proposed since other factors such as age, 
CKD and other comorbidities have been shown to increase 
the risk of AKI (4,5).
Iodinated contrast media is widely used in daily medical 
practice both in invasive procedures such as angiographies 
and non-invasive imaging studies including computed 
tomography. Because of the risk of AKI following contrast 
exposure, clinicians are often hesitant to use it for patients 
with CKD.
There is a lack of randomized control trials in this 
field but recent retrospective studies have suggested that 
intravenous contrast does not increase the risk of developing 
AKI, even in patients with advanced CKD (3). Current 
guidelines do not give a clear guidance for clinicians 
considering contrast use in patients with CKD. The 
paper by Davenport et al. “Use of Intravenous Iodinated 
Contrast Media in Patients with Kidney Disease: Consensus 
Statements from the American College of Radiology and 
the National Kidney Foundation” (6) aims to standardize 
and improve the care of CKD patients that require studies 
that involve iodinated contrast.
The consensus is limited to intravenous contrast use 
and does not cover the intraarterial use, for example for 
coronary angiographies. The authors review the literature, 
first by covering definitions and classifications of CI-
AKI and CA-AKI, followed by an overview of diagnosis, 
risk assessment and prophylactic treatment. The authors 
propose fifteen consensus statements based on existing 
evidence and compare them to guidelines from American 
College of Radiology (ACR)(4) and Kidney Disease 
Improving Global Outcomes (KDIGO) (5) regarding CI-
AKI and CA-AKI.
The key points from the statements are:
 KDIGO criteria for AKI should be used to diagnose 
CI-AKI and CA-AKI. Several definitions have been 
used to define AKI over the years and although the 
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consensus publication for AKI, the KDIGO criteria, 
has increased consistency and allowed comparisons 
between AKI studies, there is still been a discrepancy 
in definitions of AKI following contrast exposure. 
 The authors make a distinction between CA-AKI 
and CI-AKI in their risk assessment. The risk of 
CA-AKI is low in patients with low stage CKD but 
increases with growing stages and is as high as 30% 
in patients with estimated glomerular filtration rate 
(eGFR) less than 30 mL/min/1.73 m2. On the other 
hand, the risk of CI-AKI is uncertain since there 
are no prospective studies that compare contrast 
exposure with no contrast. Some studies have 
questioned the true existence of CI-AKI while others 
have shown an increased risk in patients with eGFR 
less than 30 mL/ min/1.73 m2. 
 Other risk factors for CA-AKI include diabetes, 
hypotension, hypoperfusion of the kidneys and 
nephrotoxic agents.
 There does not seem to be a clinically significant 
difference in the risk of CI-AKI between low-
osmolarity and isoosmotic contrast media, but 
high-osmolarity contrast media should not be used 
intravenously.
 Prophylaxis with intravenous isotonic fluid is 
indicated in patients with AKI, patients with 
eGFR less than 30 mL/min/1.73 m2 who are not 
receiving maintenance dialysis and patients on 
dialysis with residual kidney function. Prophylaxis 
may be considered in high risk patients with eGFR 
between 30–44 mL/min/1.73 m2. The dose and 
rate of resuscitation is uncertain and differs based 
on patients’ condition and comorbidity. Other 
prophylactic measures such as n-acetylcysteine have 
not shown clear benefit. 
 Non-essential nephrotoxic agents should be withheld 
prior to contrast exposure. The data regarding 
renin-angiotensin-aldosterone system inhibitors 
is conflicting but the authors recommend that the 
drugs should be discontinued 48 hours prior to 
elective CT.
 Contrast media dose should not be reduced below a 
known diagnostic threshold in patients at high risk 
of CI-AKI, which had previously been recommended 
in the KDIGO guidelines.
In summary, it is now accepted that the risk of AKI 
following contrast exposure is lower than previously been 
assumed, and mostly affects patients with advanced CKD. 
Contrast is only one of many risk factors for AKI in these 
patients and the term CA-AKI is now being used rather 
than CI-AKI. Imaging studies using intravenous contrast 
can be vital in diagnosing an underlying condition, and 
withholding contrast to patients considered at risk for CA-
AKI could lead to a delay in diagnosis and treatment of 
their underlying condition, that could prove more harmful 
than the contrast. However, in patients with very advanced 
CKD, the possible risk of AKI expediting the progression 
to end-stage renal disease and requirement for renal 
replacement therapy cannot be completely overlooked. 
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